Versartis fails with Phase III trial of growth hormone drug

Endocrine-focused biopharma company Versartis has announced that its VELOCITY Phase III trial of somavaratan in pediatric growth hormone deficiency (GHD) did not meet its primary endpoint of non-inferiority.

Non-inferiority versus daily growth hormone was not demonstrated in the intent to treat population for the primary efficacy variable, height velocity at 12 months.